Literature DB >> 18675565

Relative expression of different Ikaros isoforms in childhood acute leukemia.

Alexander N Meleshko1, Ludmila V Movchan, Michael V Belevtsev, Tatjana V Savitskaja.   

Abstract

Ikaros is a zinc-finger transcriptional factor playing an essential role in lymphoid lineage commitment and differentiation. Animal models and analysis of human Ikaros in leukemic cells demonstrate deregulation of Ikaros expression. Short isoforms with a truncated DNA-binding domain suppress functions of Ikaros in a dominant-negative manner. Previous studies demonstrated that human leukemias are heterogeneous for Ikaros expression. We estimate the relative level of Ikaros mRNA transcripts in 80 childhood ALL cases in comparison with AML and healthy donor groups. We detected eight major isoforms and several minor mutant isoforms in most patients with acute lymphoblastic and myeloid leukemia and in healthy donors, but the relative level of expression varied. The relatively high level of Ik4A isoform, rarely mentioned in previous reports, was detected in all analyzed groups. The ratio between functional and all isoforms was used to determine functional activity of Ikaros. The ratio was significantly less in AML (p=0.027) and BCR-ABL positive ALL (p=0.0028) than in healthy bone marrow. We found a negative association between the Ikaros ratio and myeloid coexpression in B-cell ALL, the most prominent was for CD15. The Ikaros ratio positively correlates with CD5 and negatively with CD7 expression in T-ALL. We suggest that an anti-proliferation and anti-activation effect of full-length Ikaros may be mediated through regulation of CD5 and CD7.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18675565     DOI: 10.1016/j.bcmd.2008.06.006

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  9 in total

Review 1.  Expression of different functional isoforms in haematopoiesis.

Authors:  Godfrey Grech; Joel Pollacco; Mark Portelli; Keith Sacco; Shawn Baldacchino; Justine Grixti; Christian Saliba
Journal:  Int J Hematol       Date:  2013-12-01       Impact factor: 2.490

2.  Variations in mRNA and protein levels of Ikaros family members in pediatric T cell acute lymphoblastic leukemia.

Authors:  Julie L Mitchell; Thomas M Yankee
Journal:  Ann Transl Med       Date:  2016-10

3.  Role of Ikaros in T-cell acute lymphoblastic leukemia.

Authors:  Philippe Kastner; Susan Chan
Journal:  World J Biol Chem       Date:  2011-06-26

4.  Vasoactive intestinal peptide signaling axis in human leukemia.

Authors:  Glenn Paul Dorsam; Keith Benton; Jarrett Failing; Sandeep Batra
Journal:  World J Biol Chem       Date:  2011-06-26

Review 5.  MicroRNAs in B cell development and malignancy.

Authors:  Thilini R Fernando; Norma I Rodriguez-Malave; Dinesh S Rao
Journal:  J Hematol Oncol       Date:  2012-03-08       Impact factor: 17.388

6.  Signaling proteins and transcription factors in normal and malignant early B cell development.

Authors:  Patricia Pérez-Vera; Adriana Reyes-León; Ezequiel M Fuentes-Pananá
Journal:  Bone Marrow Res       Date:  2011-05-20

7.  Expression of Ik6 and Ik8 Isoforms and Their Association with Relapse and Death in Mexican Children with Acute Lymphoblastic Leukemia.

Authors:  Adriana Reyes-León; Rocío Juárez-Velázquez; Alma Medrano-Hernández; Teresa Cuenca-Roldán; Consuelo Salas-Labadía; María Del Pilar Navarrete-Meneses; Roberto Rivera-Luna; Gerardo López-Hernández; Rogelio Paredes-Aguilera; Patricia Pérez-Vera
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

8.  An investigation of methylation pattern changes in the IKZF1 promoter in patients with childhood B-cell acute lymphoblastic leukemia.

Authors:  Mina Rahmani; Masoumeh Fardi; Majid Farshdousti Hagh; Abbas Ali Hosseinpour Feizi; Mehdi Talebi; Saeed Solali
Journal:  Blood Res       Date:  2019-06-25

Review 9.  IKAROS-Associated Diseases in 2020: Genotypes, Phenotypes, and Outcomes in Primary Immune Deficiency/Inborn Errors of Immunity.

Authors:  Hye Sun Kuehn; Cristiane J Nunes-Santos; Sergio D Rosenzweig
Journal:  J Clin Immunol       Date:  2021-01-03       Impact factor: 8.317

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.